BridgeBio Pharma Inc
BBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.4B
Close$
$-76.74
211.9% downside
Current Fair Value
211.9% downsideOvervalued by 211.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.40 Billion |
|---|---|
| Enterprise Value | $15.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.79 |
| Beta | 0.97 |
| Outstanding Shares | 195,785,884 |
Return
| Return on Equity | 27.68% |
|---|---|
| Return on Assets | -57.20% |
| Return on Invested Capital | -186.30% |
Valuation & Multiples
| P/E Ratio | -19.15 |
|---|---|
| PEG | 117.34 |
| Price to Sales | 22.85 |
| Price to Book Ratio | -5.27 |
| Enterprise Value to Revenue | 22.46 |
| Enterprise Value to EBIT | -25.02 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.16 |
| Debt to Equity | -0.99 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$220.91 M
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
$288.74 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 16.52% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.11%▼ 100.18% |
|---|---|
| Total Invested | $14.47M▼ 99.90% |
| Investors Holding | 38▼ 476.00% |
ESG Score
No data
About BridgeBio Pharma Inc
CEO: Neil Kumar